| Proteomic Analysis Revealed the Potential Role of MAGE-D2 in the Therapeutic Targeting of Triple-Negative Breast Cancer. | Proteomic Analysis Revealed the Potential Role of MAGE-D2 in the Therapeutic Targeting of Triple-Negative Breast Cancer.
Shi X, Liu C, Zheng W, Cao X, Li W, Zhang D, Zhu J, Zhang X, Chen Y., Free PMC Article | 02/1/2024 |
| Identification of a novel intronic mutation of MAGED2 gene in a Chinese family with antenatal Bartter syndrome. | Identification of a novel intronic mutation of MAGED2 gene in a Chinese family with antenatal Bartter syndrome.
Yan X, Hu Y, Zhang X, Gao X, Zhao Y, Peng H, Ouyang L, Zhang C., Free PMC Article | 01/31/2024 |
| MAGED2 Depletion Promotes Stress-Induced Autophagy by Impairing the cAMP/PKA Pathway. | MAGED2 Depletion Promotes Stress-Induced Autophagy by Impairing the cAMP/PKA Pathway.
Nasrah S, Radi A, Daberkow JK, Hummler H, Weber S, Seaayfan E, Kömhoff M., Free PMC Article | 09/19/2023 |
| Reciprocal Regulation of MAGED2 and HIF-1alpha Augments Their Expression under Hypoxia: Role of cAMP and PKA Type II. | Reciprocal Regulation of MAGED2 and HIF-1α Augments Their Expression under Hypoxia: Role of cAMP and PKA Type II.
Seaayfan E, Nasrah S, Quell L, Radi A, Kleim M, Schermuly RT, Weber S, Laghmani K, Kömhoff M., Free PMC Article | 11/29/2022 |
| MAGED2 controls vasopressin-induced aquaporin-2 expression in collecting duct cells. | MAGED2 controls vasopressin-induced aquaporin-2 expression in collecting duct cells.
Reusch B, Bartram MP, Dafinger C, Palacio-Escat N, Wenzel A, Fenton RA, Saez-Rodriguez J, Schermer B, Benzing T, Altmüller J, Beck BB, Rinschen MM. | 03/5/2022 |
| MAGED2 mutations explained 9% of cases of antenatal Bartter syndrome in a French cohort, and accounted for 38% of patients without other characterized mutations and for 44% of male probands of negative cases. | Prevalence of Novel MAGED2 Mutations in Antenatal Bartter Syndrome.
Legrand A, Treard C, Roncelin I, Dreux S, Bertholet-Thomas A, Broux F, Bruno D, Decramer S, Deschenes G, Djeddi D, Guigonis V, Jay N, Khalifeh T, Llanas B, Morin D, Morin G, Nobili F, Pietrement C, Ryckewaert A, Salomon R, Vrillon I, Blanchard A, Vargas-Poussou R., Free PMC Article | 09/21/2019 |
| MAGED2 loss of function is the cause of an X-linked transient form of antenatal Bartter's syndrome. Moreover, our findings showed that MAGE-D2 promotes the biogenesis of kidney membrane transporters. | MAGED2: a novel form of antenatal Bartter's syndrome.
Kömhoff M, Laghmani K. | 02/2/2019 |
| Increased expression of MAGE-D2 mRNA was associated with distant metastasis in Gastric Cancer. | The Expression of Melanoma-Associated Antigen D2 Both in Surgically Resected and Serum Samples Serves as Clinically Relevant Biomarker of Gastric Cancer Progression.
Kanda M, Nomoto S, Oya H, Takami H, Shimizu D, Hibino S, Hashimoto R, Kobayashi D, Tanaka C, Yamada S, Fujii T, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y. | 10/22/2016 |
| MAGE-D2 is a dynamic protein whose shuttling properties could suggest a role in cell cycle regulation. | Melanoma antigen-D2: A nucleolar protein undergoing delocalization during cell cycle and after cellular stress.
Pirlot C, Thiry M, Trussart C, Di Valentin E, Piette J, Habraken Y. | 06/11/2016 |
| We found that MAGED2 mutations caused X-linked polyhydramnios with prematurity and a severe but transient form of antenatal Bartter's syndrome. | Polyhydramnios, Transient Antenatal Bartter's Syndrome, and MAGED2 Mutations.
Laghmani K, Beck BB, Yang SS, Seaayfan E, Wenzel A, Reusch B, Vitzthum H, Priem D, Demaretz S, Bergmann K, Duin LK, Göbel H, Mache C, Thiele H, Bartram MP, Dombret C, Altmüller J, Nürnberg P, Benzing T, Levtchenko E, Seyberth HW, Klaus G, Yigit G, Lin SH, Timmer A, de Koning TJ, Scherjon SA, Schlingmann KP, Bertrand MJ, Rinschen MM, de Backer O, Konrad M, Kömhoff M. | 05/28/2016 |
| these results identify the expression of MAGE-D2 suppresses TRAIL receptor 2 and protects againstas TRAIL-induced apoptosis | The melanoma-associated antigen MAGE-D2 suppresses TRAIL receptor 2 and protects against TRAIL-induced apoptosis in human melanoma cells.
Tseng HY, Chen LH, Ye Y, Tay KH, Jiang CC, Guo ST, Jin L, Hersey P, Zhang XD. | 01/26/2013 |
| Observational study of gene-disease association. (HuGE Navigator) | New genetic associations detected in a host response study to hepatitis B vaccine.
Davila S, Froeling FE, Tan A, Bonnard C, Boland GJ, Snippe H, Hibberd ML, Seielstad M. | 04/7/2010 |
| Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) | Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
Walker LC, Waddell N, Ten Haaf A, kConFab Investigators, Grimmond S, Spurdle AB. | 03/13/2008 |
| MAGED2, a novel protein, is a p53-dissociator. | MAGED2: a novel p53-dissociator.
Papageorgio C, Brachmann R, Zeng J, Culverhouse R, Zhang W, McLeod H. | 01/21/2010 |
| Maged2 is mainly expressed in tissues of mesodermal origin | Comparative expression analysis of the MAGED genes during embryogenesis and brain development.
Bertrand M, Huijbers I, Chomez P, De Backer O. | 01/21/2010 |
| Expression pattern and further characterization of human MAGED2 and identification of rodent orthologues | Expression pattern and further characterization of human MAGED2 and identification of rodent orthologues.
Langnaese K, Kloos DU, Wehnert M, Seidel B, Wieacker P. | 01/21/2010 |
| Results identified a cDNA clone, corresponding to MAGE D2 mRNA, from primary human bronchial epithelial cells which exhibits increased expression in vitro after treatment with all-trans retinoic acid. | Identification of a novel MAGE D2 antisense RNA transcript in human tissues.
Harper R, Xu C, Di P, Chen Y, Privalsky M, Wu R. | 01/21/2010 |